PubMed · 8288352
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
V R Dharnidharka, M Agrawal, V P Dandge. 1993. Acyclovir.. https://pubmed.ncbi.nlm.nih.gov/8288352/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The Epstein-Barr virus (EBV) and human immunodeficiency virus type 1 (HIV-1) can coinfect resting B cells, leading to EBV-carrying lymphoblastoid cell lines (LCLs) persistently infected with HIV-1. LCLs established from coinfected peripheral blood lymphocytes (PBLs) differed from LCLs derived from HIV-1-infected cell lines, in that the majority if not all of the cells expressed gp120 and a high percentage produced infectious HIV-1 after continuous passage for 6-9 months. Restriction analysis of the putative HIV-1 provirus revealed that persistently infected LCLs carried variable copies of primarily unintegrated circular and/or linear forms of HIV-1 DNA. This extrachromosomal location is strikingly different from that of the one to three copies of integrated proviral DNA deleted in persistently infected T cell and monocytic cell lines. Anti-gp120 monoclonal antibody and 3'-azido-3'-deoxythymidine (AZT) inhibited HIV-1 expression and reduced HIV-1 DNA copy number in persistently infected LCLs, supporting the hypothesis that unintegrated HIV-1 DNA accumulates primarily as a result of superinfection. We propose that the extrachromosomal location of the HIV-1 DNA contributes to the semipermissive nature of B cell infection by HIV-1.
BACKGROUND: We describe a 1-year-old female who underwent living-related liver transplantation for biliary atresia and developed Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder. This disorder was resolved after withdrawal of immunosuppression therapy and administration of a high dose of acyclovir. METHODS: To quantify the extent of EBV activation and EBV load in peripheral blood, we measured the levels of EBV-infected peripheral lymphocytes by in situ hybridization (ISH) of EBV-encoded small mRNA 1 (EBER1). RESULTS: The decline in the number of EBER1-positive lymphocytes (from 362/50,000 mononuclear cells to 0/50,000) after treatment was in accord with the patient's clinical improvement. CONCLUSIONS: This finding showed that quantitative analysis of EBV-infected peripheral lymphocytes by ISH of EBER1 is very useful for monitoring the EBV load and response to treatment of patients with EBV-related disorders. Furthermore, ISH may become an important tool for the early diagnosis and prevention of life-threatening posttransplant lymphoproliferative disorder in posttransplant patients.
Explore the source record for details and available documents.